Welcome! You are visiting the MyeloRx web site.

Home
About Us
Contact Us
Site Map
Lead Compounds
Clinical Efficacy - Leuke
Natural Products
Our Strategy
Intellectual Property
Targets
Acute Myeloid Leukemia
Lead Compound - MRx102
MRx102
AML Xenograft Model (MV4-
Pilot Toxicity
Summary
Acute Myeloid Leukemia (AML)
 
A rapid proliferation of white blood cells which accumulate in the bone marrow and interfere with the production of normal cells
 
Most common acute leukemia affecting adults
Orphan drug-type indication - 10,500 new cases per year
Unmet medical need, particularly in elderly patient population
Only 20-30% of patients experience long term disease-free survival